Can a new access tool make polyp removal faster and safer?

NCT ID NCT07723937

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a device called GelPOINT® Path can improve the removal of colorectal polyps during a procedure known as endoscopic submucosal dissection (ESD). The device is designed to give doctors better access, stable air pressure, and clearer views inside the colon. Researchers will enroll 30 adults with certain types of colorectal polyps and measure how fast and safely the polyps can be removed, as well as track any complications for about four weeks afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GelPOINT® Path transanal access platform used during endoscopic submucosal dissection
What this could lead to
If successful, this approach could make polyp removal faster and safer, reducing complications and improving outcomes for patients with hard-to-reach colorectal polyps.
What could go wrong
This is a small, early feasibility study with only 30 participants, so results may not apply broadly. The device may not improve outcomes or could introduce new risks like infection or injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMA COLON POLYP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.